Conference item icon

Conference item : Abstract

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors

Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1093/annonc/mdw383.61

Authors


More from this funder
Name:
Centre for Drug Development Disclosure
Publisher:
Oxford University Press
Journal:
Annals of Oncology More from this journal
Volume:
27
Issue:
S6
Article number:
1261P
Publication date:
2016-10-01
Acceptance date:
2016-07-20
DOI:
EISSN:
1569-8041
ISSN:
0923-7534
Subtype:
Abstract
Pubs id:
pubs:719427
UUID:
uuid:9108ca55-a19b-4f53-a76d-065fd4d411df
Local pid:
pubs:719427
Source identifiers:
719427
Deposit date:
2018-08-17

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP